Skip to main content
Clinical Trials/IRCT201609105563N8
IRCT201609105563N8
Recruiting
Phase 2

Comparison of suppressive hormonal therapy(LD tablet) with aspiration in regression of ovarian endometrioma

Vice chancellor for Research,Tabriz University Of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Endometriosis of ovary.
Sponsor
Vice chancellor for Research,Tabriz University Of Medical Sciences
Enrollment
50
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Vice chancellor for Research,Tabriz University Of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • womens aged 15\-45; unilateral endometrioma, endometrioma diagnosis with ultrasound; CA 125\<100; mass size less than or equal to 6 cm
  • Exclusion criteria:
  • the possibility of malignancy; contraindications of LD pill; ischemic heart disease or previous history of it; current breast cancer; liver tumors (benign and malignant))

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Evaluation of the effectiveness of platelet-rich plasma in the treatment of Asherman's syndromeAsherman syndrome.Intrauterine synechiaeN85.6
IRCT20200316046789N1Esfahan University of Medical Sciences60
Unknown
Not Applicable
Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot FlashesHot FlashesNight Sweats
NCT00547001Hartford Hospital235
Completed
Phase 3
Comparative effects of 2 types of hormone replacement therapy on climacteric symptomsmenopause.Menopausal and female climacteric states
IRCT138809032766N1Tarbiat Maodares University150
Active, not recruiting
Not Applicable
Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hormonal therapyFemale patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapyMedDRA version: 14.1Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-000155-16-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
Active, not recruiting
Not Applicable
Effets du traitement hormonal substitutif et du raloxifène sur les cellules dendritiques plasmacytoïdes et les lymphocytes B chez les femmes ménopausées - Estrimmune
EUCTR2009-017144-14-FRCentre Hospitalier de Toulouse